Singal AG, Nagar SP, Hitchens A, Davis KL, Iyer S. Real-world effectiveness of Lenvatinib monotherapy in previously treated unresectable hepatocellular carcinoma in US clinical practice. Cancer Rep (Hoboken). 2023 Jan;6(1):e1679. doi: 10.1002/cnr2.1679
Schlatter F, Piquerez A, Habermacher M, Ragettli MS, Roosli M, Brink M, Cajochen C, Probst-Hensch N, Foraster M, Wunderli J-M. Validation of large scale noise exposure modelling by long-term measurements. Noise Mapp. 2017 Dec 22;4:75-86. doi: 10.1515/noise-2017-0006
Henk HJ, Kaye JA, Rothman KJ, Becker LK, Legg JC, Li X. Variation by age in neutropenic complications among patients with cancer receiving chemotherapy. Community Oncol. 2013 Jan 1;10(1):16-26.
Oglesby A, Sherif B, Odom D, Leahy M, Qian Y. Time and costs associated with preparing and administering zoledronic acid in patients with breast or prostate cancer and metastatic bone disease. Community Oncol. 2009 Nov 1;6(11):494-502.
Buchanan A, Sugg Skinner C, Calingaert B, Schildkraut J, King R, Marcom K. Cancer genetic counseling in rural North Carolina oncology clinics: program establishment and patient characteristics. Community Oncol. 2009;6(2):70-7.